The ASCO Post
@ascopost.bsky.social
News and views from the world of clinical oncology and hematology
🗣️ Matthew Strickland, MD, discusses phase IIb TERRIFIC data evaluating neoadjuvant tislelizumab + chemoradiotherapy vs chemo(radio)therapy for patients with locally advanced gastric/GEJ adenocarcinoma.
🎥 Watch the video: https://ow.ly/LcNf50Y7JNK
🎥 Watch the video: https://ow.ly/LcNf50Y7JNK
February 2, 2026 at 8:30 PM
🗣️ Matthew Strickland, MD, discusses phase IIb TERRIFIC data evaluating neoadjuvant tislelizumab + chemoradiotherapy vs chemo(radio)therapy for patients with locally advanced gastric/GEJ adenocarcinoma.
🎥 Watch the video: https://ow.ly/LcNf50Y7JNK
🎥 Watch the video: https://ow.ly/LcNf50Y7JNK
🚨 Cancer workforce shortages threaten patient access & research progress, according to a report from the President’s Cancer Panel.
🔹Report by Mitchel S. Berger, MD & Carol L. Brown, MD
Learn about recommendations for addressing shortages 👉 https://ow.ly/nEeA50Y5oX2
🔹Report by Mitchel S. Berger, MD & Carol L. Brown, MD
Learn about recommendations for addressing shortages 👉 https://ow.ly/nEeA50Y5oX2
January 29, 2026 at 6:30 PM
🚨 Cancer workforce shortages threaten patient access & research progress, according to a report from the President’s Cancer Panel.
🔹Report by Mitchel S. Berger, MD & Carol L. Brown, MD
Learn about recommendations for addressing shortages 👉 https://ow.ly/nEeA50Y5oX2
🔹Report by Mitchel S. Berger, MD & Carol L. Brown, MD
Learn about recommendations for addressing shortages 👉 https://ow.ly/nEeA50Y5oX2
🚨 New American Cancer Society study: States that limit/don’t allow short-term health plans saw delays in timely cancer treatment initiation after diagnosis. Health insurance is a major factor in survival. #CancerCare
✍️ Jingxuan Zhao, PhD
🔗 https://ow.ly/kPMk50Y4UpZ
✍️ Jingxuan Zhao, PhD
🔗 https://ow.ly/kPMk50Y4UpZ
January 28, 2026 at 7:30 PM
🚨 New American Cancer Society study: States that limit/don’t allow short-term health plans saw delays in timely cancer treatment initiation after diagnosis. Health insurance is a major factor in survival. #CancerCare
✍️ Jingxuan Zhao, PhD
🔗 https://ow.ly/kPMk50Y4UpZ
✍️ Jingxuan Zhao, PhD
🔗 https://ow.ly/kPMk50Y4UpZ
🧠 Targeted therapy shows activity in aggressive meningiomas.
In a phase II Alliance trial, abemaciclib slowed tumor growth in patients with NF2 mutations or CDK pathway–altered meningiomas.
Priscilla Brastianos, MD
🔗 https://ow.ly/4ZCp50Y3UoA
In a phase II Alliance trial, abemaciclib slowed tumor growth in patients with NF2 mutations or CDK pathway–altered meningiomas.
Priscilla Brastianos, MD
🔗 https://ow.ly/4ZCp50Y3UoA
January 27, 2026 at 1:00 PM
🧠 Targeted therapy shows activity in aggressive meningiomas.
In a phase II Alliance trial, abemaciclib slowed tumor growth in patients with NF2 mutations or CDK pathway–altered meningiomas.
Priscilla Brastianos, MD
🔗 https://ow.ly/4ZCp50Y3UoA
In a phase II Alliance trial, abemaciclib slowed tumor growth in patients with NF2 mutations or CDK pathway–altered meningiomas.
Priscilla Brastianos, MD
🔗 https://ow.ly/4ZCp50Y3UoA
🕊️ “A Battle With My Blood” - the final essay by Tatiana Celia Kennedy Schlossberg, recounting her diagnosis with aggressive acute myeloid leukemia and her search for meaning, hope, and memory.
https://ascopost.com/issues/january-25-2026/a-battle-with-my-blood/
https://ascopost.com/issues/january-25-2026/a-battle-with-my-blood/
January 26, 2026 at 6:15 PM
🕊️ “A Battle With My Blood” - the final essay by Tatiana Celia Kennedy Schlossberg, recounting her diagnosis with aggressive acute myeloid leukemia and her search for meaning, hope, and memory.
https://ascopost.com/issues/january-25-2026/a-battle-with-my-blood/
https://ascopost.com/issues/january-25-2026/a-battle-with-my-blood/
🆕 The January 2026 issue of The ASCO Post features: highlights from ASH 2025, SABCS 2025, and GI 2026; and an essay written by Tatiana Schlossberg about her battle with AML reprinted following her death.
Don’t miss this issue 👉 https://ascopost.com/issues/january-25-2026/
Don’t miss this issue 👉 https://ascopost.com/issues/january-25-2026/
January 23, 2026 at 6:15 PM
🆕 The January 2026 issue of The ASCO Post features: highlights from ASH 2025, SABCS 2025, and GI 2026; and an essay written by Tatiana Schlossberg about her battle with AML reprinted following her death.
Don’t miss this issue 👉 https://ascopost.com/issues/january-25-2026/
Don’t miss this issue 👉 https://ascopost.com/issues/january-25-2026/
📢 The FDA has issued a draft guidance for the use of minimal residual disease and complete response as endpoints in multiple myeloma clinical trials to support accelerated approval.
https://ow.ly/Q5bc50Y1n9K
https://ow.ly/Q5bc50Y1n9K
January 22, 2026 at 9:45 PM
📢 The FDA has issued a draft guidance for the use of minimal residual disease and complete response as endpoints in multiple myeloma clinical trials to support accelerated approval.
https://ow.ly/Q5bc50Y1n9K
https://ow.ly/Q5bc50Y1n9K
⚖️💊 FDA & EMA set global principles for good, responsible AI use in drug development.
New guidance outlines 🔟 best practices to ensure AI tools support safe, ethical, and effective drug innovation.
Read the full list of principles here 👉 https://ow.ly/C9Ka50Y0BC0
New guidance outlines 🔟 best practices to ensure AI tools support safe, ethical, and effective drug innovation.
Read the full list of principles here 👉 https://ow.ly/C9Ka50Y0BC0
January 21, 2026 at 6:45 PM
⚖️💊 FDA & EMA set global principles for good, responsible AI use in drug development.
New guidance outlines 🔟 best practices to ensure AI tools support safe, ethical, and effective drug innovation.
Read the full list of principles here 👉 https://ow.ly/C9Ka50Y0BC0
New guidance outlines 🔟 best practices to ensure AI tools support safe, ethical, and effective drug innovation.
Read the full list of principles here 👉 https://ow.ly/C9Ka50Y0BC0
📊American Cancer Society’s Cancer Stats, 2026:
⬆️ 5-yr survival rate for all cancers = 70%
⬆️ Significantly increased 5-yr survival rates: multiple myeloma, liver cancer, metastatic melanoma, regional lung cancer
⬇️ Mortality rate dropped by 34% through 2023
https://ow.ly/bukz50Y0gX9
⬆️ 5-yr survival rate for all cancers = 70%
⬆️ Significantly increased 5-yr survival rates: multiple myeloma, liver cancer, metastatic melanoma, regional lung cancer
⬇️ Mortality rate dropped by 34% through 2023
https://ow.ly/bukz50Y0gX9
January 20, 2026 at 7:30 PM
📊American Cancer Society’s Cancer Stats, 2026:
⬆️ 5-yr survival rate for all cancers = 70%
⬆️ Significantly increased 5-yr survival rates: multiple myeloma, liver cancer, metastatic melanoma, regional lung cancer
⬇️ Mortality rate dropped by 34% through 2023
https://ow.ly/bukz50Y0gX9
⬆️ 5-yr survival rate for all cancers = 70%
⬆️ Significantly increased 5-yr survival rates: multiple myeloma, liver cancer, metastatic melanoma, regional lung cancer
⬇️ Mortality rate dropped by 34% through 2023
https://ow.ly/bukz50Y0gX9
🥫 Study highlights possible links between select food preservatives and cancer risk:
• Potassium sorbate, potassium nitrate, total acetates → ⬆️ overall & breast cancer risk
• Sodium nitrite → ⬆️ prostate cancer risk
🔹Hasenböhler et al |
https://ow.ly/oJlT50XWc7r
• Potassium sorbate, potassium nitrate, total acetates → ⬆️ overall & breast cancer risk
• Sodium nitrite → ⬆️ prostate cancer risk
🔹Hasenböhler et al |
https://ow.ly/oJlT50XWc7r
January 13, 2026 at 6:15 PM
🥫 Study highlights possible links between select food preservatives and cancer risk:
• Potassium sorbate, potassium nitrate, total acetates → ⬆️ overall & breast cancer risk
• Sodium nitrite → ⬆️ prostate cancer risk
🔹Hasenböhler et al |
https://ow.ly/oJlT50XWc7r
• Potassium sorbate, potassium nitrate, total acetates → ⬆️ overall & breast cancer risk
• Sodium nitrite → ⬆️ prostate cancer risk
🔹Hasenböhler et al |
https://ow.ly/oJlT50XWc7r
📊 Final data from phase III AGO-OVAR 2.29:
No significant OS or PFS benefit with atezolizumab + bevacizumab + nonplatinum chemo in recurrent ovarian cancer, though a paclitaxel subgroup showed a favorable OS signal.
🔸 Philipp Harter, MD
🔗 https://ow.ly/PYjn50XVIWN
No significant OS or PFS benefit with atezolizumab + bevacizumab + nonplatinum chemo in recurrent ovarian cancer, though a paclitaxel subgroup showed a favorable OS signal.
🔸 Philipp Harter, MD
🔗 https://ow.ly/PYjn50XVIWN
January 12, 2026 at 9:45 PM
📊 Final data from phase III AGO-OVAR 2.29:
No significant OS or PFS benefit with atezolizumab + bevacizumab + nonplatinum chemo in recurrent ovarian cancer, though a paclitaxel subgroup showed a favorable OS signal.
🔸 Philipp Harter, MD
🔗 https://ow.ly/PYjn50XVIWN
No significant OS or PFS benefit with atezolizumab + bevacizumab + nonplatinum chemo in recurrent ovarian cancer, though a paclitaxel subgroup showed a favorable OS signal.
🔸 Philipp Harter, MD
🔗 https://ow.ly/PYjn50XVIWN
🔬COMMIT trial shows triplet therapy (FOLFOX + bevacizumab + atezolizumab) significantly improved PFS vs atezolizumab alone in 1L dMMR/MSI-H mCRC (HR = 0.43)
• 12-mo PFS: 67% vs 35%
Caio Max Sao Pedro Rocha Lima, MD, MS
🔗 https://ow.ly/Mpgl50XT5Yw
• 12-mo PFS: 67% vs 35%
Caio Max Sao Pedro Rocha Lima, MD, MS
🔗 https://ow.ly/Mpgl50XT5Yw
January 8, 2026 at 10:15 PM
🔬COMMIT trial shows triplet therapy (FOLFOX + bevacizumab + atezolizumab) significantly improved PFS vs atezolizumab alone in 1L dMMR/MSI-H mCRC (HR = 0.43)
• 12-mo PFS: 67% vs 35%
Caio Max Sao Pedro Rocha Lima, MD, MS
🔗 https://ow.ly/Mpgl50XT5Yw
• 12-mo PFS: 67% vs 35%
Caio Max Sao Pedro Rocha Lima, MD, MS
🔗 https://ow.ly/Mpgl50XT5Yw
🍔A study found higher fast-food spending by block in Alabama was linked to more cases of early-onset colorectal cancer, while higher fruit & vegetable spending had a strong protective effect.🥦
🔹 Blake Buchalter, MPH, PhD
🔗 https://ow.ly/urH650XT29I
🔹 Blake Buchalter, MPH, PhD
🔗 https://ow.ly/urH650XT29I
January 7, 2026 at 8:45 PM
🍔A study found higher fast-food spending by block in Alabama was linked to more cases of early-onset colorectal cancer, while higher fruit & vegetable spending had a strong protective effect.🥦
🔹 Blake Buchalter, MPH, PhD
🔗 https://ow.ly/urH650XT29I
🔹 Blake Buchalter, MPH, PhD
🔗 https://ow.ly/urH650XT29I
🔮 The path forward isn’t AI instead of clinicians—but human+AI collaboration, according to Michael Sobolev, PhD et al.
🔹 Public trust, including for AI’s role in #cancer detection (currently ~15% of survey respondents), grows with experience.
🔗 https://ow.ly/EOYs50XS1A7
🔹 Public trust, including for AI’s role in #cancer detection (currently ~15% of survey respondents), grows with experience.
🔗 https://ow.ly/EOYs50XS1A7
January 6, 2026 at 11:15 PM
🔮 The path forward isn’t AI instead of clinicians—but human+AI collaboration, according to Michael Sobolev, PhD et al.
🔹 Public trust, including for AI’s role in #cancer detection (currently ~15% of survey respondents), grows with experience.
🔗 https://ow.ly/EOYs50XS1A7
🔹 Public trust, including for AI’s role in #cancer detection (currently ~15% of survey respondents), grows with experience.
🔗 https://ow.ly/EOYs50XS1A7
🔬Postoperative ctDNA testing may help personalize adjuvant therapy in patients with colon cancer—identifying those most likely to benefit from NSAIDs like celecoxib added to chemotherapy.
👨⚕️ George Q. Zhang, MD, MPH
🔗 https://ow.ly/XuPs50XS1p3
👨⚕️ George Q. Zhang, MD, MPH
🔗 https://ow.ly/XuPs50XS1p3
January 6, 2026 at 7:25 PM
🔬Postoperative ctDNA testing may help personalize adjuvant therapy in patients with colon cancer—identifying those most likely to benefit from NSAIDs like celecoxib added to chemotherapy.
👨⚕️ George Q. Zhang, MD, MPH
🔗 https://ow.ly/XuPs50XS1p3
👨⚕️ George Q. Zhang, MD, MPH
🔗 https://ow.ly/XuPs50XS1p3
📊Phase III inMIND trial: Adding tafasitamab to lenalidomide + rituximab significantly improved PFS in patients with relapsed/refractory Follicular Lymphoma (22.4 vs 13.9 months; HR = 0.43).
🔺Laurie H. Sehn, MD
🔗 https://ow.ly/PYBQ50XS1kF
🔺Laurie H. Sehn, MD
🔗 https://ow.ly/PYBQ50XS1kF
January 6, 2026 at 3:01 PM
📊Phase III inMIND trial: Adding tafasitamab to lenalidomide + rituximab significantly improved PFS in patients with relapsed/refractory Follicular Lymphoma (22.4 vs 13.9 months; HR = 0.43).
🔺Laurie H. Sehn, MD
🔗 https://ow.ly/PYBQ50XS1kF
🔺Laurie H. Sehn, MD
🔗 https://ow.ly/PYBQ50XS1kF
New meta-analysis shows that GLP-1 receptor agonists likely have little or no effect on obesity-related #cancer risk.
Longer-term, cancer-specific studies still needed.
🔸Ko et al
🔗 https://ascopost.com/news/december-2025/study-explores-association-of-glp-1-ras-with-risk-of-obesity-related-cancers/
Longer-term, cancer-specific studies still needed.
🔸Ko et al
🔗 https://ascopost.com/news/december-2025/study-explores-association-of-glp-1-ras-with-risk-of-obesity-related-cancers/
January 5, 2026 at 5:20 PM
New meta-analysis shows that GLP-1 receptor agonists likely have little or no effect on obesity-related #cancer risk.
Longer-term, cancer-specific studies still needed.
🔸Ko et al
🔗 https://ascopost.com/news/december-2025/study-explores-association-of-glp-1-ras-with-risk-of-obesity-related-cancers/
Longer-term, cancer-specific studies still needed.
🔸Ko et al
🔗 https://ascopost.com/news/december-2025/study-explores-association-of-glp-1-ras-with-risk-of-obesity-related-cancers/
🩸 Potential new standard of care in newly diagnosed Multiple Myeloma
ADVANCE trial from ASCO25: Adding daratumumab to KRd significantly improved MRD negativity vs KRd alone—without added toxicity in selected patients.
👨⚕️ C. Ola Landgren, MD, PhD
🔗 https://ow.ly/Cx2L50XNJ7S
ADVANCE trial from ASCO25: Adding daratumumab to KRd significantly improved MRD negativity vs KRd alone—without added toxicity in selected patients.
👨⚕️ C. Ola Landgren, MD, PhD
🔗 https://ow.ly/Cx2L50XNJ7S
January 2, 2026 at 9:00 PM
🩸 Potential new standard of care in newly diagnosed Multiple Myeloma
ADVANCE trial from ASCO25: Adding daratumumab to KRd significantly improved MRD negativity vs KRd alone—without added toxicity in selected patients.
👨⚕️ C. Ola Landgren, MD, PhD
🔗 https://ow.ly/Cx2L50XNJ7S
ADVANCE trial from ASCO25: Adding daratumumab to KRd significantly improved MRD negativity vs KRd alone—without added toxicity in selected patients.
👨⚕️ C. Ola Landgren, MD, PhD
🔗 https://ow.ly/Cx2L50XNJ7S
Happy New Year from The ASCO Post!
January 1, 2026 at 3:01 PM
Happy New Year from The ASCO Post!
🔬 TAP Highlight of 2025: Is this the end of cancer research as we know it?
A proposed 15% cap on NIH indirect (F&A) costs threatens labs, clinical trials, and decades of progress in #CancerResearch—jeopardizing patients and innovation nationwide.
🔗 https://ow.ly/IGA850XNJ41
A proposed 15% cap on NIH indirect (F&A) costs threatens labs, clinical trials, and decades of progress in #CancerResearch—jeopardizing patients and innovation nationwide.
🔗 https://ow.ly/IGA850XNJ41
December 31, 2025 at 7:00 PM
🔬 TAP Highlight of 2025: Is this the end of cancer research as we know it?
A proposed 15% cap on NIH indirect (F&A) costs threatens labs, clinical trials, and decades of progress in #CancerResearch—jeopardizing patients and innovation nationwide.
🔗 https://ow.ly/IGA850XNJ41
A proposed 15% cap on NIH indirect (F&A) costs threatens labs, clinical trials, and decades of progress in #CancerResearch—jeopardizing patients and innovation nationwide.
🔗 https://ow.ly/IGA850XNJ41
#YearInReview: In matched-related donor stem cell transplantation, cyclophosphamide + calcineurin inhibition significantly improved GVHD- & relapse-free survival vs standard therapy—without added toxicity. From #EHA25
🔸 David Curtis, MBBS, PhD
🔗 https://ow.ly/ZfQ450XNJ1R
🔸 David Curtis, MBBS, PhD
🔗 https://ow.ly/ZfQ450XNJ1R
December 30, 2025 at 2:01 PM
#YearInReview: In matched-related donor stem cell transplantation, cyclophosphamide + calcineurin inhibition significantly improved GVHD- & relapse-free survival vs standard therapy—without added toxicity. From #EHA25
🔸 David Curtis, MBBS, PhD
🔗 https://ow.ly/ZfQ450XNJ1R
🔸 David Curtis, MBBS, PhD
🔗 https://ow.ly/ZfQ450XNJ1R
TAP Highlight of 2025 - Update in early HER2+ Breast Cancer:
• Adjuvant: T-DXd beat T-DM1 in high-risk residual disease (HR = 0.47)
• Neoadjuvant: T-DXd→THP improved pCR (67.3% vs 56.3%)
• Signals for fewer CNS events (DB05)
🔗 https://ow.ly/3BCO50XNIRO
• Adjuvant: T-DXd beat T-DM1 in high-risk residual disease (HR = 0.47)
• Neoadjuvant: T-DXd→THP improved pCR (67.3% vs 56.3%)
• Signals for fewer CNS events (DB05)
🔗 https://ow.ly/3BCO50XNIRO
December 29, 2025 at 4:45 PM
TAP Highlight of 2025 - Update in early HER2+ Breast Cancer:
• Adjuvant: T-DXd beat T-DM1 in high-risk residual disease (HR = 0.47)
• Neoadjuvant: T-DXd→THP improved pCR (67.3% vs 56.3%)
• Signals for fewer CNS events (DB05)
🔗 https://ow.ly/3BCO50XNIRO
• Adjuvant: T-DXd beat T-DM1 in high-risk residual disease (HR = 0.47)
• Neoadjuvant: T-DXd→THP improved pCR (67.3% vs 56.3%)
• Signals for fewer CNS events (DB05)
🔗 https://ow.ly/3BCO50XNIRO
🚨 ICYMI: NCCN early 2025 updates impacted practice across:
• 🫙 Bladder: periop/sandwich IO + chemo; HER2-targeted options
• 🫁 NSCLC/SCLC: more periop + consolidation IO; tarlatamab added
• 🧬 mCRC: expanded IO + BRAF-targeted combos
• 🩸 Myeloma: quadruplets gaining ground
🔗 https://ow.ly/1j7j50XNIzM
• 🫙 Bladder: periop/sandwich IO + chemo; HER2-targeted options
• 🫁 NSCLC/SCLC: more periop + consolidation IO; tarlatamab added
• 🧬 mCRC: expanded IO + BRAF-targeted combos
• 🩸 Myeloma: quadruplets gaining ground
🔗 https://ow.ly/1j7j50XNIzM
December 26, 2025 at 7:00 PM
🚨 ICYMI: NCCN early 2025 updates impacted practice across:
• 🫙 Bladder: periop/sandwich IO + chemo; HER2-targeted options
• 🫁 NSCLC/SCLC: more periop + consolidation IO; tarlatamab added
• 🧬 mCRC: expanded IO + BRAF-targeted combos
• 🩸 Myeloma: quadruplets gaining ground
🔗 https://ow.ly/1j7j50XNIzM
• 🫙 Bladder: periop/sandwich IO + chemo; HER2-targeted options
• 🫁 NSCLC/SCLC: more periop + consolidation IO; tarlatamab added
• 🧬 mCRC: expanded IO + BRAF-targeted combos
• 🩸 Myeloma: quadruplets gaining ground
🔗 https://ow.ly/1j7j50XNIzM
Wishing you a wonderful holiday season!
December 25, 2025 at 5:01 PM
Wishing you a wonderful holiday season!
👉 Major takeaways from Treatment Advances in Malignant Hematology from NCCNhem25:
• Immunotherapy-first strategies expanding
• MRD driving treatment intensity
• Biomarkers guiding frontline choices
• Outpatient management of cellular therapies
🔗 https://ow.ly/bU3350XNIyw
• Immunotherapy-first strategies expanding
• MRD driving treatment intensity
• Biomarkers guiding frontline choices
• Outpatient management of cellular therapies
🔗 https://ow.ly/bU3350XNIyw
December 24, 2025 at 4:02 PM
👉 Major takeaways from Treatment Advances in Malignant Hematology from NCCNhem25:
• Immunotherapy-first strategies expanding
• MRD driving treatment intensity
• Biomarkers guiding frontline choices
• Outpatient management of cellular therapies
🔗 https://ow.ly/bU3350XNIyw
• Immunotherapy-first strategies expanding
• MRD driving treatment intensity
• Biomarkers guiding frontline choices
• Outpatient management of cellular therapies
🔗 https://ow.ly/bU3350XNIyw